WASHINGTON	washington	WASHINGTON
Reuters	reuter	Reuters
-	-	-
Mylan	mylan	Mylan
NL	nl	NL
Chief	chief	Chief
Executive	execut	Executive
Officer	offic	Officer
Heather	heather	Heather
Bresch	bresch	Bresch
will	will	will
appear	appear	appear
at	at	at
a	a	a
Sept	sept	Sept
.	.	.
21	21	21
congressional	congression	congressional
hearing	hear	hearing
over	over	over
price	price	price
increases	increas	increase
for	for	for
its	it	it
EpiPen	epipen	EpiPen
emergency	emerg	emergency
allergy	allergi	allergy
treatment	treatment	treatment
,	,	,
the	the	the
U	u	U
.	.	.
S	s	S
.	.	.
House	hous	House
of	of	of
Representatives	repres	Representatives
Oversight	oversight	Oversight
Committee	committe	Committee
said	said	said
in	in	in
a	a	a
statement	statement	statement
on	on	on
Wednesday	wednesday	Wednesday
.	.	.
Mylan	mylan	Mylan
has	has	ha
been	been	been
widely	wide	widely
criticized	critic	criticized
,	,	,
including	includ	including
by	by	by
U	u	U
.	.	.
S	s	S
.	.	.
Democratic	democrat	Democratic
presidential	presidenti	presidential
candidate	candid	candidate
Hillary	hillari	Hillary
Clinton	clinton	Clinton
,	,	,
for	for	for
sharply	sharpli	sharply
raising	rais	raising
the	the	the
price	price	price
of	of	of
EpiPens	epipen	EpiPens
,	,	,
which	which	which
are	are	are
carried	carri	carried
by	by	by
people	peopl	people
with	with	with
life	life	life
-threatening	-threaten	-threatening
allergies	allergi	allergy
.	.	.
Mylan	mylan	Mylan
,	,	,
which	which	which
acquired	acquir	acquired
the	the	the
product	product	product
in	in	in
2007	2007	2007
,	,	,
recently	recent	recently
raised	rais	raised
the	the	the
list	list	list
price	price	price
for	for	for
a	a	a
pair	pair	pair
of	of	of
EpiPen	epipen	EpiPen
auto	auto	auto
-injectors	-injector	-injectors
to	to	to
600	600	600
.	.	.
The	the	The
price	price	price
has	has	ha
been	been	been
rising	rise	rising
from	from	from
a	a	a
cost	cost	cost
of	of	of
about	about	about
100	100	100
in	in	in
2008	2008	2008
.	.	.
Mylan	mylan	Mylan
spokeswoman	spokeswoman	spokeswoman
Nina	nina	Nina
Devlin	devlin	Devlin
confirmed	confirm	confirmed
that	that	that
Bresch	bresch	Bresch
will	will	will
attend	attend	attend
the	the	the
hearing	hear	hearing
.	.	.
Heather	heather	Heather
is	is	is
very	veri	very
good	good	good
at	at	at
being	be	being
able	abl	able
to	to	to
give	give	give
an	an	an
answer	answer	answer
without	without	without
offering	offer	offering
much	much	much
information	inform	information
,	,	,
said	said	said
Evercore	evercor	Evercore
ISI	isi	ISI
analyst	analyst	analyst
Umer	umer	Umer
Raffat	raffat	Raffat
,	,	,
adding	ad	adding
that	that	that
he	he	he
will	will	will
be	be	be
watching	watch	watching
for	for	for
any	ani	any
other	other	other
issues	issu	issue
that	that	that
might	might	might
be	be	be
raised	rais	raised
by	by	by
the	the	the
Committee	committe	Committee
.	.	.
A	a	A
probe	probe	probe
into	into	into
EpiPen	epipen	EpiPen
pricing	price	pricing
by	by	by
a	a	a
U	u	U
.	.	.
S	s	S
.	.	.
Senate	senat	Senate
subcommittee	subcommitte	subcommittee
was	was	wa
announced	announc	announced
on	on	on
Sept	sept	Sept
.	.	.
7	7	7
.	.	.
Bresch	bresch	Bresch
is	is	is
the	the	the
daughter	daughter	daughter
of	of	of
U	u	U
.	.	.
S	s	S
.	.	.
Senator	senat	Senator
Joe	joe	Joe
Manchin	manchin	Manchin
,	,	,
a	a	a
Democrat	democrat	Democrat
from	from	from
West	west	West
Virginia	virginia	Virginia
.	.	.
The	the	The
House	hous	House
panel	panel	panel
co	co	co
-chairmen	-chairmen	-chairmen
,	,	,
Republican	republican	Republican
Representative	repres	Representative
Jason	jason	Jason
Chaffetz	chaffetz	Chaffetz
and	and	and
Democratic	democrat	Democratic
Representative	repres	Representative
Elijah	elijah	Elijah
Cummings	cum	Cummings
,	,	,
noted	note	noted
there	there	there
is	is	is
.	.	.
.	.	.
.	.	.
justified	justifi	justified
outrage	outrag	outrage
from	from	from
families	famili	family
and	and	and
schools	school	school
across	across	across
the	the	the
country	countri	country
struggling	struggl	struggling
to	to	to
afford	afford	afford
the	the	the
high	high	high
cost	cost	cost
of	of	of
EpiPens	epipen	EpiPens
.	.	.
The	the	The
committee	committe	committee
planned	plan	planned
to	to	to
look	look	look
at	at	at
how	how	how
to	to	to
spur	spur	spur
competition	competit	competition
in	in	in
the	the	the
EpiPen	epipen	EpiPen
market	market	market
and	and	and
speed	speed	speed
approval	approv	approval
by	by	by
the	the	the
Food	food	Food
and	and	and
Drug	drug	Drug
Administration	administr	Administration
FDA	fda	FDA
of	of	of
generic	generic	generic
alternatives	altern	alternative
,	,	,
according	accord	according
to	to	to
the	the	the
statement	statement	statement
.	.	.
In	in	In
response	respons	response
to	to	to
the	the	the
furor	furor	furor
,	,	,
Mylan	mylan	Mylan
last	last	last
month	month	month
said	said	said
it	it	it
would	would	would
sell	sell	sell
its	it	it
own	own	own
generic	generic	generic
version	version	version
of	of	of
EpiPen	epipen	EpiPen
for	for	for
300	300	300
.	.	.
Teva	teva	Teva
Pharmaceutical	pharmaceut	Pharmaceutical
Industries	industri	Industries
,	,	,
which	which	which
for	for	for
years	year	year
has	has	ha
been	been	been
working	work	working
on	on	on
developing	develop	developing
a	a	a
generic	generic	generic
alternative	altern	alternative
to	to	to
EpiPen	epipen	EpiPen
,	,	,
said	said	said
last	last	last
week	week	week
that	that	that
it	it	it
hopes	hope	hope
to	to	to
gain	gain	gain
U	u	U
.	.	.
S	s	S
.	.	.
approval	approv	approval
by	by	by
late	late	late
2017	2017	2017
or	or	or
early	earli	early
20018	20018	20018
.	.	.
EpiPen	epipen	EpiPen
,	,	,
which	which	which
has	has	ha
annual	annual	annual
sales	sale	sale
of	of	of
about	about	about
1	1	1
billion	billion	billion
,	,	,
delivers	deliv	delivers
a	a	a
potentially	potenti	potentially
life	life	life
-saving	-save	-saving
dose	dose	dose
of	of	of
epinephrine	epinephrin	epinephrine
by	by	by
injection	inject	injection
into	into	into
the	the	the
thigh	thigh	thigh
to	to	to
counter	counter	counter
dangerous	danger	dangerous
allergic	allerg	allergic
reactions	reaction	reaction
,	,	,
including	includ	including
to	to	to
peanuts	peanut	peanut
and	and	and
bee	bee	bee
stings	sting	sting
.	.	.
Mylan	mylan	Mylan
owns	own	owns
94	94	94
percent	percent	percent
of	of	of
the	the	the
market	market	market
for	for	for
such	such	such
auto	auto	auto
-injected	-inject	-injected
devices	devic	device
.	.	.
The	the	The
committee	committe	committee
said	said	said
it	it	it
also	also	also
planned	plan	planned
to	to	to
call	call	call
as	as	a
a	a	a
witness	wit	witness
Dr	dr	Dr
Doug	doug	Doug
Throckmorton	throckmorton	Throckmorton
,	,	,
the	the	the
FDA	fda	FDA
s	s	s
deputy	deputi	deputy
director	director	director
at	at	at
the	the	the
Center	center	Center
for	for	for
Drug	drug	Drug
Evaluation	evalu	Evaluation
and	and	and
Research	research	Research
.	.	.
